Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ARVN
stocks logo

ARVN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
37.26M
-37.06%
-0.555
-11.84%
21.89M
-88.41%
-0.784
-168.76%
22.06M
-1.5%
-0.807
-3.87%
Estimates Revision
The market is revising Upward the revenue expectations for Arvinas, Inc. (ARVN) for FY2025, with the revenue forecasts being adjusted by 2.37% over the past three months. During the same period, the stock price has changed by 60.28%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.37%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-27.55%
In Past 3 Month
Stock Price
Go Up
up Image
+60.28%
In Past 3 Month
Wall Street analysts forecast ARVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARVN is 20.62 USD with a low forecast of 6.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast ARVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARVN is 20.62 USD with a low forecast of 6.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
6 Hold
1 Sell
Moderate Buy
Current: 12.550
sliders
Low
6.00
Averages
20.62
High
110.00
Current: 12.550
sliders
Low
6.00
Averages
20.62
High
110.00
Stephens
Loganathan
Overweight
maintain
$14 -> $15
2025-11-10
Reason
Stephens
Loganathan
Price Target
$14 -> $15
2025-11-10
maintain
Overweight
Reason
Stephens analyst Sudan Loganathan raised the firm's price target on Arvinas to $15 from $14 and keeps an Overweight rating on the shares. Q3 results were broadly in-line, notes the analyst, who sees forward value in ARV-393, ARV-102, and ARV-806 given "encouraging" early data across these assets and now incorporates ARV-102 into the firm's valuation framework.
BTIG
Buy
upgrade
$10 -> $14
2025-10-30
Reason
BTIG
Price Target
$10 -> $14
2025-10-30
upgrade
Buy
Reason
BTIG raised the firm's price target on Arvinas to $14 from $10 and keeps a Buy rating on the shares. Shares have sold off following the vepdeg reset, but the combination of current valuation, potential of KRASG12D as a target in large indications such as NSCLC and PDAC, and ability for ARV-806 to clinically differentiate all have the firm leaning into the stock ahead of the data, the analyst tells investors in a research note, adding that the firm is also including ARV-806 in its model.
Goldman Sachs
Neutral -> Sell
downgrade
$8 -> $6
2025-10-15
Reason
Goldman Sachs
Price Target
$8 -> $6
2025-10-15
downgrade
Neutral -> Sell
Reason
Goldman Sachs downgraded Arvinas to Sell from Neutral with a price target of $6, down from $8. The firm says the "rapidly evolving" competitive landscape for hormone receptor-positive/HER2-negative metastatic breast cancer puts the company's vepdegestrant at increasing risk of obsolescence. Arvinas competitors' progress has taken some of the interest away from vepdegestrant and has made an out-licensing deal more challenging, the analyst tells investors in a research note. Goldman thinks the shares will largely trade on cash burn considerations.
Stephens
Sudan Loganathan
Overweight
to
Overweight
downgrade
$16 -> $14
2025-09-18
Reason
Stephens
Sudan Loganathan
Price Target
$16 -> $14
2025-09-18
downgrade
Overweight
to
Overweight
Reason
Stephens analyst Sudan Loganathan lowered the firm's price target on Arvinas (ARVN) to $14 from $16 and keeps an Overweight rating on the shares after the company announced an update on its collaboration with Pfizer (PFE) for the co-development of vepdegestrant. The companies will out-license commercialization rights to a third party and have begun the partner search process and Arvinas will refocus its operations by reducing vepdeg related expenses, cutting about 15% of its workforce and reallocating capital to ARV-102, ARV-393, and ARV-806, notes the analyst, who calls this "an unsurprising outcome." Given the increased uncertainty surrounding vepdeg's commercial outlook, the firm reduced its estimate of Arvinas' attributed peak sales for vepdeg in 2035 to $641.2M from $966.2M previously forecast.
BTIG
Buy
downgrade
$16 -> $10
2025-09-18
Reason
BTIG
Price Target
$16 -> $10
2025-09-18
downgrade
Buy
Reason
BTIG lowered the firm's price target on Arvinas (ARVN) to $10 from $16 and keeps a Buy rating on the shares. The company provided an update on its collaboration agreement with Pfizer (PFE) for vepdegestrant, noting the two will jointly select a third party for outl-icensing and commercialization, the analyst tells investors in a research note. The firm says Arvinas management is optimistic on finding a new partner before the June 2026 FDA action note, but highlights the "very tight timeline." BTIG views the news as a "reset" for Arvinas which provides an opportunity to focus on its internal programs for oncology and neuroscience. It sees an attractive entry point for the shares.
Barclays
NULL -> Overweight
initiated
$16
2025-09-16
Reason
Barclays
Price Target
$16
2025-09-16
initiated
NULL -> Overweight
Reason
Barclays initiated coverage of Arvinas with an Overweight rating and $16 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Arvinas Inc (ARVN.O) is -4.21, compared to its 5-year average forward P/E of 77.89. For a more detailed relative valuation and DCF analysis to assess Arvinas Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
77.89
Current PE
-4.21
Overvalued PE
459.08
Undervalued PE
-303.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-13.93
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
33.73
Undervalued EV/EBITDA
-61.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
23.28
Current PS
0.00
Overvalued PS
49.28
Undervalued PS
-2.72
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ARVN News & Events

Events Timeline

(ET)
2025-11-05
07:15:13
Arvinas anticipates sufficient funds to last through the second half of 2028.
select
2025-11-05
07:14:55
Arvinas Announces Q3 Earnings Per Share of 48 Cents, Below Consensus Estimate of 74 Cents
select
2025-10-24 (ET)
2025-10-24
16:02:13
Arvinas unveils preclinical findings for ARV-806
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-26Globenewswire
Arvinas to Participate in Piper Sandler Healthcare Conference on December 4
  • Executive Participation: Arvinas' Chief Medical Officer Noah Berkowitz and Chief Financial Officer Andrew Saik will engage in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4 in New York, showcasing the company's cutting-edge advancements in biotechnology.
  • Clinical Development Progress: Arvinas is advancing multiple investigational drugs, including ARV-102 targeting neurodegenerative disorders and ARV-393 for relapsed/refractory non-Hodgkin lymphoma, highlighting the company's innovative potential in the targeted protein degradation space.
  • Technological Platform Advantage: Through its PROTAC protein degrader platform, Arvinas is developing therapies designed to effectively degrade disease-causing proteins, aiming to improve patient quality of life and reflecting the company's strategic positioning in treating severe diseases.
  • Market Positioning: Arvinas focuses on developing treatments for various life-threatening diseases, indicating its significant role in the biopharmaceutical industry, particularly in the innovative drug development for cancer and neurodegenerative disorders.
[object Object]
Preview
9.0
10-25Newsfilter
Arvinas Unveils Preclinical Findings for ARV-806 Showcasing Strong and Unique Efficacy in KRAS G12D-Mutated Cancer Models at the 2025 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Treatments

  • ARV-806 Efficacy: ARV-806, a PROTAC KRAS G12D degrader, showed significant tumor growth inhibition and robust degradation of KRAS G12D in preclinical models of pancreatic, colorectal, and lung cancers, demonstrating its potential as a best-in-class therapy for these cancers.

  • Differentiation from Other Agents: The data presented highlight ARV-806's superior potency and durability compared to other G12D targeting agents, with over 25-fold greater potency in reducing cancer cell proliferation and over 40-fold higher potency in degrading KRAS G12D protein.

  • Clinical Development: Arvinas is currently evaluating ARV-806 in a Phase 1 clinical trial for patients with KRAS G12D-mutated advanced solid tumors, indicating a commitment to addressing high unmet needs in this area.

  • Innovative Approach: The use of targeted protein degradation through ARV-806 aims to overcome historical challenges in treating undruggable KRAS mutations, potentially leading to meaningful benefits for patients with these mutations.

[object Object]
Preview
9.0
10-20Newsfilter
Patient-Reported Outcomes from the VERITAC-2 Trial Indicate Clinical Benefits of Vepdegestrant for Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer After Endocrine Therapy

  • Clinical Trial Results: The Phase 3 VERITAC-2 trial showed that vepdegestrant significantly improved patient-reported outcomes, delaying deterioration in quality of life, pain, and daily functioning compared to fulvestrant in patients with ESR1-mutated ER+/HER2- advanced breast cancer.

  • Potential Treatment Option: Vepdegestrant is being developed as a monotherapy for advanced breast cancer and has received Fast Track designation from the FDA, indicating its potential as a meaningful treatment option for patients previously treated with endocrine therapy.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Arvinas Inc (ARVN) stock price today?

The current price of ARVN is 12.55 USD — it has decreased -0.95 % in the last trading day.

arrow icon

What is Arvinas Inc (ARVN)'s business?

Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

arrow icon

What is the price predicton of ARVN Stock?

Wall Street analysts forecast ARVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARVN is 20.62 USD with a low forecast of 6.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Arvinas Inc (ARVN)'s revenue for the last quarter?

Arvinas Inc revenue for the last quarter amounts to 41.90M USD, decreased -59.08 % YoY.

arrow icon

What is Arvinas Inc (ARVN)'s earnings per share (EPS) for the last quarter?

Arvinas Inc. EPS for the last quarter amounts to -0.48 USD, decreased -29.41 % YoY.

arrow icon

What changes have occurred in the market's expectations for Arvinas Inc (ARVN)'s fundamentals?

The market is revising Upward the revenue expectations for Arvinas, Inc. (ARVN) for FY2025, with the revenue forecasts being adjusted by 2.37% over the past three months. During the same period, the stock price has changed by 60.28%.
arrow icon

How many employees does Arvinas Inc (ARVN). have?

Arvinas Inc (ARVN) has 430 emplpoyees as of December 05 2025.

arrow icon

What is Arvinas Inc (ARVN) market cap?

Today ARVN has the market capitalization of 806.01M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free